A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

Jason J. Luke,Manish Sharma,Rachel E. Sanborn,Gregory M. Cote,Johanna C. Bendell,Glen J. Weiss,Alexey Berezhnoy,Sharad K. Sharma,Paul A. Moore,Ezio Bonvini,Kerri Cali,Jan Baughman,Jon M. Wigginton,Brad Sumrow

A phase I, first-in-human, open label, dose-escalation and cohort expansion study of MGD019, a bispecific DART protein binding PD-1 and CTLA-4 in patients with unresectable or metastatic neoplasms.

2019

Jason J. Luke
Manish Sharma
Rachel E. Sanborn
Gregory M. Cote
Johanna C. Bendell
Glen J. Weiss
Alexey Berezhnoy
Sharad K. Sharma
Paul A. Moore
Ezio Bonvini
Kerri Cali
Jan Baughman
Jon M. Wigginton
Brad Sumrow

TPS2661Background: Immune checkpoint molecules, including CTLA-4 and PD-1, attenuate the duration and strength of adaptive immune responses to limit immune-mediated tissue damage. Tumors may inhibi...

Keywords:

Cohort
Plasma protein binding
Oncology
Pathology
CTLA-4
Medicine
Internal medicine
in patient
Cancer research
first in human
open label
Immune system
dose escalation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations